Literature DB >> 21349354

Bisphosphonates for postmenopausal osteoporosis.

Richard Eastell1, Jennifer S Walsh, Nelson B Watts, Ethel Siris.   

Abstract

Bisphosphonates are effective in reducing bone turnover, increasing BMD and reducing fracture risk in postmenopausal women with osteoporosis. The licensed bisphosphonates exhibit some differences in potency and speed of onset and offset of action. These differences mean that different agents may be more advantageous in different situations. Uncertainties still exist around the optimum duration of treatment and treatment holidays, how best to use bisphosphonates with anabolic treatments, and the benefits of treatment in patients who do not have a BMD T-score below -2.5.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349354     DOI: 10.1016/j.bone.2011.02.011

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  36 in total

1.  Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.

Authors:  Elizabeth A Swallow; Mohammad W Aref; Corinne E Metzger; Spencer Sacks; Demi R Lehmkuhler; Neal Chen; Max A Hammond; Paul R Territo; Thomas L Nickolas; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2019-07-09       Impact factor: 4.398

2.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

3.  Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate.

Authors:  Cory N Meixner; Mohammad W Aref; Aryaman Gupta; Erin M B McNerny; Drew Brown; Joseph M Wallace; Matthew R Allen
Journal:  Calcif Tissue Int       Date:  2017-02-28       Impact factor: 4.333

4.  Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats.

Authors:  K Hatori; G V Camargos; M Chatterjee; F Faot; K Sasaki; J Duyck; K Vandamme
Journal:  Osteoporos Int       Date:  2014-09-19       Impact factor: 4.507

5.  Bisphosphonate drug holiday: who, when and how long.

Authors:  Dima L Diab; Nelson B Watts
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-06       Impact factor: 5.346

6.  Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats.

Authors:  Allison R Altman-Singles; Yonghoon Jeong; Wei-Ju Tseng; Chantal Mj de Bakker; Hongbo Zhao; Carina Lott; Juhanna Robberts; Ling Qin; Lin Han; Do-Gyoon Kim; X Sherry Liu
Journal:  J Bone Miner Res       Date:  2017-06-13       Impact factor: 6.741

7.  Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.

Authors:  Matthew R Allen; Neal X Chen; Vincent H Gattone; Sharon M Moe
Journal:  Am J Nephrol       Date:  2013-11-22       Impact factor: 3.754

8.  Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease.

Authors:  Sakura Yamamoto; Atsushi Suzuki; Hitomi Sasaki; Sahoko Sekiguchi-Ueda; Shogo Asano; Megumi Shibata; Nobuki Hayakawa; Shuji Hashimoto; Kiyotaka Hoshinaga; Mitsuyasu Itoh
Journal:  J Bone Miner Metab       Date:  2012-10-18       Impact factor: 2.626

9.  Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism.

Authors:  Symeon Tournis; Eleni Fakidari; Ismene Dontas; Chrysoula Liakou; Julia Antoniou; Antonis Galanos; Helen Marketou; Konstantinos Makris; Katerina Katsalira; George Trovas; George P Lyritis; Nikolaos Papaioannou
Journal:  J Bone Miner Metab       Date:  2013-05-23       Impact factor: 2.626

10.  Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.

Authors:  K R Olsen; C Hansen; B Abrahamsen
Journal:  Osteoporos Int       Date:  2013-04-20       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.